Olux Generic Name & Formulations
Clobetasol propionate 0.05%; foam.
Treatment of plaque psoriasis of the scalp (moderate to severe) and non-scalp regions (mild to moderate).
Olux Dosage and Administration
≥12yrs: apply thin layer to affected area(s) twice daily; max 50g/week or 21 capfuls/week and 2 consecutive weeks' treatment per course. Discontinue when control is achieved. Wash hands after application. Do not occlude.
<12yrs: not recommended.
Olux Boxed Warnings
Not for oral, ophthalmic, or intravaginal use. Avoid use on face, axillae, groin, or other intertriginous areas. Do not use for diaper dermatitis or on pre-existing skin atrophy. Risk of HPA axis suppression with high-potency steroids, prolonged use, application to large surface area, use of occlusive dressings, altered skin barrier, liver failure, young age; discontinue gradually, reduce dose, or substitute with less potent corticosteroid if occurs. Increased risk of posterior subcapsular cataracts and glaucoma; monitor for visual symptoms. Treat infection if present; discontinue if infection persists or worsens. Avoid abrupt cessation in chronic use. Reevaluate periodically. Product is flammable. Pregnancy. Nursing mothers.
Olux Adverse Reactions
Burning, stinging, pruritus, erythema, skin atrophy, folliculitis, dermal cracking and fissuring, telangiectasia, striae; allergic contact dermatitis (discontinue if irritation occurs), HPA axis suppression (esp. in children); rare: Cushing's syndrome, hyperglycemia.
Olux Clinical Trials
Olux Patient Counseling